LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Erismodegib|DRUG: Placebo
Sponsor: Washington University School of Medicine